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Introduction: Hyperhomocysteinemia (HHcy) is a risk factor for venous thromboembolism, which in turn is a major cause
of chronic venous insufficiency. HHcy may be more common in patients with chronic venous insufficiency, but the cause
is unknown.
Methods: One hundred hospital outpatients (52 women; median age, 66.5 years [interquartile range, 53-77 years] with
venous disease C2-6 underwent assessment of serum vitamin B12 and folate concentration, plasma Hcy concentration, and
C677T methylene tetrahydrofolate reductase (MTHR) homozygosity with polymerase chain reaction. HHcy was defined
as greater than 15 mol/L, the 95th centile of the normal range.
Results: CEAP classification was C2 in 39 patients, C3 in 10 patients, C4 in 13 patients, C5 in 15 patients, and C6 in 23
patients, with median Hcy concentration 11.6, 11.5, 12.5, 15.1, and 18.1 mol/L, respectively (Kruskall-Wallis test, P
< .001). Overall prevalence of HHcy was 39% (P < .001, binomial test vs normal population), and was significantly
related (Pearson 2 for trend, 13.616; P < .009) to clinical grade: C2, 23%; C3, 20%; C4, 39%; C5, 53%; C6, 65%. In a
linear regression model, C6 disease was a strong independent predictor (R2  20.1%) for Hcy. Overall, 5 of 49 patients
(10%, NS compared with normal population [5%]) with C2-3 disease and 10 of 51 patients (20%) (P < .001, binomial test)
with C4-6 disease were homozygous for the C677T MTHFR polymorphism. Hcy levels and prevalence of HHcy were
negatively correlated with vitamin B12 levels (r0.248, P .021, and r0.225;, P .037, respectively). There was
no significant relationship with folate. HHcy was present in 3 patients (all with C5-6 disease) with either vitamin B12 or
folate deficiency, and in 8 of 15 patients homozygous for MTHFR C677T. No patient had HHcy, vitamin deficiency, and
C677T mutation.
Conclusion: HHcy is common in patients with chronic venous insufficiency, especially those with ulceration. However,
inasmuch as fewer than a third of patients with HHcy were C677T MTHFR homozygous or had vitamin B12 or folate
deficiency, other mechanisms must be responsible in the majority. Further work is required to determine the cause of
HHcy in chronic venous insufficiency, whether HHcy is causally related to development and progression of the disease,
and whether treatment would be beneficial. (J Vasc Surg 2003;38:904-8.)
Chronic venous insufficiency is extremely common in
Europe and North America; 30% to 40% of adults have
varicose veins (VV), 8% have skin changes, and at least 1%
have chronic venous ulceration.1,2 In most patients,
chronic venous insufficiency is due to superficial or deep
venous reflux, which may be caused by primary valvar reflux
or postthrombotic syndrome. A high proportion of pa-
tients with chronic venous ulceration have at least one
thrombophilic disorder.2,3 Deep venous thromboses oc-
curring in association with thrombophilia may be more
likely to cause postthrombotic syndrome, because they
occur earlier in life, are often recurrent and extensive, are
more resistant to endogenous fibrinolysis and therapy, and
thus cause more severe and widespread venous damage.
Many episodes of deep venous thrombosis may go unno-
ticed by patient or clinician, and the subtle changes caused
by thrombosis may be missed on venous duplex scans. This
may explain why, although many patients with varicose
veins do not subsequently have the complications of venous
disease, a significant number with seemingly only superfi-
cial venous reflux do have skin changes over many years and
later ulceration due to venous hypertension.
There is growing evidence to suggest that hyperhomo-
cysteinemia (HHcy), due to enzyme mutations or environ-
mental factors, is an independent risk factor for arterial and
venous thrombosis.4-7 The commonest mutation responsi-
ble for HHcy is the methylene tetrahydrofolate reductase
(MTHFR) C677T polymorphism, and the commonest
environmental factors are vitamin B12, vitamin B6, and
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folate deficiency.4 The purpose of the present study was to
determine the prevalence of HHcy in patients with varying
severity of chronic venous insufficiency and to examine
associated factors.
METHODS
Ethical committee approval and informed patient con-
sent were obtained. One hundred consecutive consenting
patients attending a hospital-based clinic were classified
according to CEAP on the basis of clinical findings,8 and a
nonfasting sample of blood was drawn from an antecubital
fossa vein. The sample was centrifuged immediately at
2000g for 15 minutes at 4°C, and plasma and serum were
stored at80°C. Cells were tested for the C677T MTHFR
polymorphism with the polymerase chain reaction.9 Prev-
alence of the homozygous state is estimated at 5% in the
healthy white population with no evidence of cardiovascu-
lar disease.10 Vitamin B12 (190-900 ng/L) and folate
(2.0-15.1 g/L) were measured in our validated institu-
tional laboratory with an electrochemiluminesence immu-
noassay (Roche modular analytics, Welwyn Gardens,
United Kingdom). Total plasma homocysteine (Hcy) con-
centration was determined with high-pressure liquid chro-
matography (DS 30; Drew, Cumbria, England). HHcy was
defined as greater than 15mol/L, which is the upper 95th
centile in the healthy white population.5 SPSS software
(version 11.0; SPSS, Chicago, Ill) was used for all analyses.
On the basis of preliminary work conducted by our group,
an increase in prevalence of HHcy from 5% in the healthy
white population with no cardiovascular disease11 to 15% in
our study population was considered clinically significant,
and a sample size of approximately 70 was required to
achieve a power of 82.2% at 5% significance. The Kruskal-
Wallis test was used to study differences in Hcy between
CEAP grades, and CEAP grade was correlated with patient
age and sex, and Hcy, vitamin B12, and folate concentra-
tions, with Spearman’s rho. The binomial test was used for
comparison of proportions, and 2 analysis for trends.
RESULTS
The study included 100 patients (52 women), with
median age, 66.5 years (interquartile range [IQR], 53-77
years). Median Hcy concentration was 12.6mol/L (IQR,
10.3-16.4 mol/L). CEAP classification was C2 in 39
patients, C3 in 10 patients, C4 in 13 patients, C5 in 15
patients, and C6 in 23 patients. Median Hcy concentration
was 11.6, 11.5, 12.5, 15.1, and 18.1 mol/L, respectively
(Kruskall-Wallis test; P  .001; Table I; Fig). Overall
prevalence of HHcy was 39%, (compared with 5% in the
general population11; P  .001, binomial test), and was
significantly related (Pearson 2 for trend, 13.616; P 
.009) to clinical grade: C2, 23%; C3, 20%; C4, 39%; C5,
53%; C6, 65%. Hcy levels are higher in patients with
evidence of atherosclerotic vascular disease (ischemic heart
disease, cerebrovascular or peripheral vascular disease).
However, in our study population the prevalence was small,
Table I. Relationship between CEAP clinical grade, Hcy, HHcy, vitamin B12 and folate levels and deficiency, MTHFR
C677T homozygosity, and renal insufficiency
CEAP clinical
grade
2
(n  39)
3
(n  10)
4
(n  13)
5
(n  15)
6
(n  23)
All patients
(N  100)
Median age (y)*
(IQR)
56 (46-64) 59.5 (52-67) 75 (61-80) 77 (63-80) 78 (69-84) 67 (53-77)
Median Hcy
(pmol/L)*
(IQR)
11.6 (9.2-14.0) 11.5 (9.9-13.1) 12.5 (10.7-16.0) 15.1 (11.1-16.0) 18.1 (13.7-22.4) 12.6 (10.3-16.4)
HHcy (%)† 9 (23) 2 (20) 5 (39) 8 (53) 15 (65) 39 (39)
Median folate
(IQR)
8.0 (5.99-11.45) 7.36 (5.16-9.43) 6.97 (4.43-11.01) 5.92 (4.05-6.54) 6.62 (5.48-12.26) 6.96 (5.28-10.54)
Folate deficiency 0 0 1 1 0 2
Median vitamin
B12 (IQR)
349 (292-507) 304 (195-415) 272 (245-446) 475 (320-652) 317 (258-420) 349 (271-483)
Vitamin B12
deficiency
0 1 2 0 2 5
C677T
homozygosity
(%)
3 (8) 2 (20) 3 (23) 1 (7) 6 (26) 15 (15)
HHcy and vitamin
deficiency
0 0 0 1 2 3
HHcy and
MTHFR
homozygosity
2 1 2 0 3 8
HHcy and
elevated Cr.
concentration
0 1 1 1 2 5
Hcy, Homocysteine; HHcy, hyperhomocysteinemia; MTHFR, methylene tetrahydrofolate reductase; IQR, interquartile range.
*P  0.001, Kruskal-Wallis test.
†Pearson 2  13.616; P  .009.
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with only nine patients demonstrating clinical evidence of
disease. Ankle-brachial pressure index in all patients but
one was normal (0.9).
As expected, Hcy concentration and prevalence of
HHcy were positively correlated with age (Spearman r 
0.333, 0.244; P.001, P .014, respectively) and clinical
grade (r 0.435, 0.351; both P .001), but not with sex
or presence of arterial disease. To investigate this further,
regression analysis was performed, with Hcy as the depen-
dent variable, and age, sex, and CEAP clinical grade as
independent variables (Table II). By itself, age was a weak
predictor of Hcy (coefficient, 0.09; P  .007; R2, 7.2%),
but this became insignificant when clinical grade was intro-
duced into the model. Power calculation suggests that, if
the age effect were of the magnitude suggested in the
model, 250 to 300 subjects would be required. With addi-
tion of CEAP clinical grade as a set of factors, with CEAP
C2 as baseline, grades C3 to C5 had no significant predictive
power for Hcy. In contrast, C6 disease was a strong inde-
pendent predictor (R2  20.1%) for Hcy, whether com-
pared with other grades separately (coefficient, 5.021 
1.42 (SE); P  .001) or together (coefficient, 4.36 
1.184; P  .000).
Overall, 15 patients were homozygous for the MTHFR
C677T mutation; 5 of 49 with C2-3 disease (10%, not
significant when compared with the healthy population,
estimated at 5% of the white population10) and 10 of 51
with C4-6 disease (20% vs healthy population; P  .001,
binomial test). Hcy concentration and prevalence of HHcy
were negatively correlated with vitamin B12 levels (r 
0.248,0.225; P .021, P .037, respectively). There
was no significant relationship with folate concentration.
Table II. Multiple regression analysis of relationship between venous disease, age, and sex
Coefficient SE t P R2 (%)
Age Age (continuous) 0.09 0.033 2.76 0.007 7.2
Age  C, C2
(baseline)
Age (continuous) 0.028 0.037 0.74 0.462
C3 0.55 0.67 0.33 0.74
C4 0.69 1.60 0.43 0.67
C5 1.84 1.58 1.17 0.25
C6 5.02 1.42 3.53 0.001 20.1
Age  C6, C2-5
(baseline)
Age (continuous) 0.048 0.033 1.46 0.147
C6 4.36 1.18 3.69 0.000 18.6
C6 and age, 50
(baseline)
C6 4.18 1.18 3.55 0.001
Age 50-69 0.318 1.29 0.25 0.806
Age 70 1.76 1.31 1.35 0.181 20.1
C6, age, sex C6 4.37 1.19 3.67 0.000
Age (continuous) 0.047 0.033 1.42 0.159
Sex 0.225 0.0941 2.39 0.019 18.7
Interaction effects Age and C 0.129 0.082 1.57 0.119 20.6
Indicator variables were used for categories C3-6, with C2 as baseline.
Relationship between homocysteine concentration (Hcy) and CEAP clinical grade. Vertical bars, Interquartile range.
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HHcy was present in 3 patients, all with C5-6 disease, with
either vitamin B12 or folate deficiency, and in 8 of 15
patients homozygous for MTHFR C677T. No patient had
HHcy, vitamin deficiency, and C677T mutation.
DISCUSSION
The main finding of this study is that mild to moderate
HHcy (15-30 mol/L) is extremely common in patients
with chronic venous insufficiency, especially those with
open ulceration. However, the reasons for this striking
observation, and its clinical significance, require further
study. It is widely believed that most mild to moderate
HHcy in the general population is due to vitamin deficien-
cy12 and enzyme defects, especially the MTHFR C677T
mutation.4,5 Although we found a significant inverse rela-
tionship between plasma Hcy and serum vitamin B12 con-
centration, few patients actually had serum vitamin B12
concentration below the lower limit of normal. Similarly,
few patients had clear evidence of folate deficiency, and
there was no relationship between serum folate and plasma
Hcy concentrations. It has been suggested that serum levels
significantly underestimate vitamin B12 deficiency and that
methylmalonic acid concentration is more meaningful.5
This group is currently investigating whether dietary vita-
min B12 and folate supplementation will reduce Hcy levels.
With regard to the C677T MTHFR mutation, overall
15% of our patients were homozygous, compared with an
estimated 5% of the healthy white population. Of interest,
prevalence of the mutation was significantly higher in com-
plicated C4-6 disease (20%) compared with uncomplicated
C2-3 disease (10%). However, it was present in only 20% of
patients with HHcy. The importance of this mutation in
venous thrombosis is controversial,7,10,13 and it has been
suggested that in the presence of adequate folate this
mutation per se is unlikely to have a significant effect on
Hcy concentration.6 Patients with chronic venous insuffi-
ciency have an increased prevalence of several other throm-
bophilic disorders associated with arterial and venous
thrombosis. This and present data are in keeping with the
“multihit” paradigm of thrombophilia and thrombosis, in
which various inherited and acquired factors act in concert
to raise individuals above their thrombotic threshold.7,13,14
What other issues are raised by the present study? First,
inasmuch as plasma Hcy concentration and chronic venous
insufficiency both increase with age, it is possible that the
current observations are, in reality, an effect of age rather
than severity of disease. However, at regression analysis,
ulceration but not age was a significant independent pre-
dictor for Hcy.
Second, there is no universally accepted definition of
HHcy. In this study we followed common convention by
defining HHcy as Hcy concentration greater than the 95th
percentile for the general population, although this figure
of 15 mol/L is controversial.5,12 Furthermore, this “nor-
mal” range includes individuals with venous disease. The
implication therefore is that the differences in plasma Hcy
concentration between those with and without venous
disease might be even greater than indicated by the present
data. This group is currently accumulating plasma Hcy data
in an age-matched and sex-matched control population
without any clinical or duplex scan evidence of venous
disease.
Third, there is continuing debate over whether Hcy
concentration should be measured in fasting samples. Lo-
gistically this is difficult, and unless the patient has ingested
a large protein load (unlikely in this study, because virtually
all blood samples were drawn mid-morning), nonfasting
concentrations will be elevated by only 10% or less.15 We
believe it unlikely that use of fasting samples would have
significantly affected the present data and their interpreta-
tion.
Fourth, is the strong relationship observed between
plasma Hcy concentration and increasing severity of venous
disease associative or causal? If so, does chronic venous
insufficiency cause HHcy, or does HHcy contribute to
development and progression of the disease? With regard to
the latter, it is interesting to note that in the linear regres-
sion model only the presence of open ulceration (C6), not
healed ulceration (C5) or skin changes (C4), significantly
predicted HHcy. We believe that this is most likely an effect
of relatively small subgroup numbers. However, it cannot
be completely discounted that the presence of an open
wound in some way causes, or at least exacerbates, HHcy.
It is hoped that ongoing longitudinal studies in larger
numbers of patients will address these questions.
Last, the hypothesis underlying this work is that throm-
bophilic disorders, of which HHcy is but one, are an
important risk factor for development and progression of
chronic venous insufficiency. At present the relationships
between HHcy, the pattern of venous disease on duplex
ultrasound scans, and the natural history of the disease are
unknown. It is hoped that ongoing longitudinal studies of
the effects of treatment, including compression, surgery,
and dietary supplementation, on plasma HHcy in relation
to ulcer healing and recurrence will enable us to determine
whether the present data merely represent an interesting
observation or a clinically meaningful pathogenetic mech-
anism that is open to therapeutic modification.
In conclusion, HHcy is recognized as a risk factor for
venous thrombosis, and is present in as many as 65% of
patients with chronic venous insufficiency. However, the
cause of HHcy remains unclear; only about a third of
patients are homozygous for the C677T MTHFR muta-
tion, or have vitamin B12 or folate deficiency. Further
studies are required to define the nature and clinical signif-
icance of the observed relationship between Hcy and
chronic venous insufficiency.
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